ConductScience.org, home

Comparison · NCT03079869-sae

Ferric Citrate - Hemodialysis vs Ferric Citrate - Peritoneal Dialysis: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Ferric Citrate - Hemodialysis vs Ferric Citrate - Peritoneal Dialysis: serious adverse events. Trial comparisons, record NCT03079869-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03079869-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.2590.1320.447wilson
Risk in group 20.370.2150.558wilson
Risk difference, group 1 minus group 2-0.111-0.3380.132newcombe hybrid score
Risk ratio, group 1 over group 20.70.3131.57log
Odds ratio, group 1 over group 20.5950.1861.9log
Number needed to treat, for one fewer participant with a serious adverse event on Ferric Citrate - Hemodialysis than on Ferric Citrate - Peritoneal Dialysis9from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Ferric Citrate - Hemodialysis
Auryxia, 210 mg ferric iron tablets equivalent to 1 g of ferric citrate are supplied as 200 tablets in 400-cc high-density polyethylene bottles.~Ferric Citrate: One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
727EG000
Group 2Ferric Citrate - Peritoneal Dialysis
Auryxia, 210 mg ferric iron tablets equivalent to 1 g of ferric citrate are supplied as 200 tablets in 400-cc high-density polyethylene bottles.~Ferric Citrate: One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
1027EG001

Harm

What it counts
Total, serious adverse events
Time frame
7 months

Source ClinicalTrials.gov

Trial

Title
Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients
NCT number
NCT03079869
Phases
PHASE4
Conditions
Hyperphosphatemia
Interventions
Ferric Citrate
Lead sponsor
Kaiser Permanente
Results first posted
2022-01-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03079869-sae